The Conference on Cell & Gene Therapy for HIV Cure
August 17-18, 2017
Fred Hutchinson Cancer Research Center
Seattle, Washington | USA
The defeatHIV Martin Delany Collaboratory, in collaboration with the Fred Hutchinson Cancer Research Center, the University of Washington Center for AIDS Research (UW CFAR) and the UW Virology Division, are pleased to host the fourth annual Conference on Cell & Gene Therapy for HIV Cure in Seattle, Washington on August 17-18, 2017. The event will be held on the campus of the Fred Hutchinson Cancer Research Center.
Born out of the desire to bring much needed attention to HIV cell and gene therapies, this conference aims to advance the pursuit of an HIV cure by bringing together an international roster of esteemed scientists to share and review the latest cell and gene therapy approaches targeting HIV. View more on the DETAILS page.
To receive the latest conference updates and announcements, subscribe to our mailing list!
Due to unforeseen events, Dr. Jennifer Doudna is unable to keynote the 2017 Conference on Cell & Gene Therapy for HIV Cure.
We are honored to announce Carl H. June, MD, as Keynote Speaker for CGT4HIVCure 2017.
Carl H. June, MD
Director of Translational Research
Abramson Cancer Center
Director of the Parker Institute for Cancer Immunotherapy and the Center for Cellular Immunotherapies
Richard W. Vague Professor in Immunotherapy
Department of Pathology and Laboratory Medicine
Perelman School of Medicine
University of Pennsylvania
Carl June is currently Director of the Center for Cellular Immunotherapies and Director of Translational Research in the Abramson Cancer Center of the University of Pennsylvania, and is an Investigator of the Abramson Family Cancer Research Institute. Dr. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School Of Medicine.
In 2011, Dr. June’s research team published findings which represented the first successful and sustained demonstration of the use of gene transfer therapy to treat cancer. Clinical trials utilizing this approach, in which patients are treated with genetically engineered versions of their own T cells, are now underway for adults with chronic lymphocytic leukemia and adults and children with acute lymphoblastic leukemia. Early results in that group show that 90 percent of patients respond to the therapy, and more recently, trials of this approach have begun for patients with other blood cancers and solid tumors including pancreatic cancer, mesothelioma, and the brain cancer glioblastoma. In 2014, it became the first personalized cellular therapy for the treatment of cancer therapy to receive the U.S. Food and Drug Administration’s prestigious Breakthrough Therapy designation.
Please view our announcement flyer Here.